Results for:(76 found)
Dec 17, 2012 12:32PM on Top StocksBy TheStreet Staff

It's a great company and stock, but expectations are high and outperformance in 2013 will be tough.

Nov 30, 2012 4:11AM on Top StocksBy Gene Marcial

Snap up shares before the spinoff for a win-win investment.

Tags: ABT
Nov 27, 2012 4:43PM on Top StocksBy Minyanville.com

New data are significant as the biotech company moves closer to filing for approval of Sofosbuvir next year.

Nov 16, 2012 10:30AM on Top StocksBy InvestorPlace

Jobless claims are being blamed on Sandy, but more pink slips could be coming -- and not because of the weather.

Nov 15, 2012 12:55PM on Top StocksBy InvestorPlace

Next-gen drugs can help power growth and income alike.

Nov 12, 2012 11:26AM on Top StocksBy Minyanville.com

Abbott also reports promising results ahead of a big medical meeting.

Tags: ABTGILD
Nov 9, 2012 3:37PM on Top StocksBy Trefis

The approval of the rheumatoid arthritis treatment will help douse recent concerns about its pipeline.

Tags: ABTJNJPFE
Nov 7, 2012 12:15PM on Top StocksBy Minyanville.com

The pharma wins US approval for a new rheumatoid arthritis pill, but Abbott's existing treatment isn't likely to suffer a meaningful hit to sales anytime soon.

VIDEO ON MSN MONEY

DATA PROVIDERS

Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.

MARKET DISPATCHES

No more Dispatches; here's where to find market news

The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.

More